Categories Earnings, Health Care

Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot

— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.

— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected

— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year

— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine

— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer

— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020

— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Key highlights from Adobe (ADBE) Q2 2021 earnings results

Adobe Systems Incorporated (NASDAQ: ADBE) reported second quarter 2021 earnings results today. Total revenue grew 23% year-over-year to $3.84 billion. GAAP net income was $1.11 billion, or $2.32 per share,

Three factors that bode well for Delta Air Lines (DAL) going forward

Shares of Delta Air Lines Inc. (NYSE: DAL) have gained 45% over the past 12 months and 11% since the beginning of this year. After a particularly distressful period, like

KR Earnings: All you need to know about Kroger Q1 2021 earnings results

The Kroger Co. (NYSE: KR) reported first-quarter 2021 earnings results today. Total company sales were $41.3 billion compared to $41.5 billion in the same period last year. Excluding fuel, sales

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top